Welcome to our dedicated page for Vital Farms SEC filings (Ticker: VITL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vital Farms’ pasture-raised promise is simple; its SEC filings are not. Whether you’re tracking how commodity feed prices hit egg margins or verifying the scale of its 300-plus family-farm network, each report holds critical details about this ethically minded food company. Stock Titan gathers every Vital Farms SEC filing in one place and layers in AI insights so you can grasp the story behind the numbers without wading through legal jargon.
Need the Vital Farms quarterly earnings report 10-Q filing? Curious about Vital Farms insider trading Form 4 transactions? Our platform delivers real-time EDGAR updates, then distills them into plain-English takeaways—revenue by product line, feed-cost sensitivity, sustainability KPIs, and more. You’ll see Vital Farms 8-K material events explained within minutes and receive concise summaries that point you straight to the line items that move the stock.
Investors use this page to:
- Monitor Vital Farms Form 4 insider transactions real-time and spot buying by executives before material announcements.
- Compare pasture-raised segment performance across periods with AI-annotated tables from each 10-Q.
- Dive into the Vital Farms annual report 10-K simplified to understand long-term supply-chain risks.
- Review the Vital Farms proxy statement executive compensation to see how pay aligns with ESG goals.
Every document—10-K, 10-Q, 8-K, Form 4, DEF 14A—is covered, refreshed instantly, and paired with machine-generated commentary. That means Vital Farms earnings report filing analysis and “understanding Vital Farms SEC documents with AI” are no longer separate tasks. Access comprehensive coverage, expert context, and actionable clarity on one dedicated page.
Vital Farms, Inc. (VITL) Form 4 filing dated 07/03/2025 discloses that Executive Chairperson, Director and >10% owner Matthew Ohayer sold an aggregate 30,000 shares of common stock on 07/01/2025 under a previously adopted Rule 10b5-1 trading plan (established 03/14/2025).
The sales were split into two blocks:
- 9,714 shares at a weighted-average price of $38.85
- 20,286 shares at a weighted-average price of $39.32
Post-transaction ownership stands at 6,858,890 directly held shares plus 716,000 shares held by a former spouse over which the reporting person retains voting control but no economic interest. The direct sale represents roughly 0.4% of Mr. Ohayer’s direct stake, leaving him with a sizeable position that continues to exceed the 10% beneficial-ownership threshold.
No derivative security transactions were reported, and no earnings or operational data were included in this filing.
Intellia Therapeutics, Inc. (NTLA) – Form 4 insider transaction
EVP & Chief Technical Officer Eliana Clark reported the sale of 1,022 common shares on 01 July 2025 at a price of $9.82 per share (transaction code “S”). The shares had been purchased a day earlier under the company’s 2016 Employee Stock Purchase Plan and were therefore treated as non-derivative shares in Table I.
Following the disposition, Clark’s direct beneficial ownership stands at 95,369 shares. No derivative securities transactions were reported in Table II, and no Rule 10b5-1 trading plan box was checked, indicating the sale was executed outside of a pre-arranged trading program.
The filing represents a 1.1 % reduction in Clark’s directly held position (1,022 / 96,391 pre-sale) and is relatively small in dollar terms (~$10,000). No other insiders are included in this filing, and there is no indication of broader strategic implications for NTLA. Investors typically monitor insider activity for sentiment signals; however, a sale of this size by one executive is generally viewed as routine portfolio management rather than a material change in outlook.
Arhaus, Inc. (NASDAQ: ARHS) filed an 8-K announcing a board change. On 27 June 2025 the Board appointed Samir Desai—currently EVP & Chief Digital and Technology Officer at Abercrombie & Fitch—as an independent Class III director. His initial term runs until the 2027 annual meeting, after which he is expected to stand for re-election. Desai will sit on the Board’s Technology Committee, bringing extensive omnichannel retail and IT leadership experience from Abercrombie & Fitch, Equinox Group and Intertex Apparel Group. To accommodate the appointment, the Board’s size rises from ten to eleven directors. Compensation will mirror that of Arhaus’s other non-employee directors and no related-party transactions were reported. Exhibit 104 (Inline XBRL cover page) accompanies the filing.
FAQ
What is the current stock price of Vital Farms (VITL)?
What is the market cap of Vital Farms (VITL)?
What products does Vital Farms produce?
How does Vital Farms ensure ethical production?
What is the significance of the stakeholder model at Vital Farms?
How does Vital Farms differentiate itself in the food industry?
How is product quality maintained at Vital Farms?
Why are pasture-raised products important?
Where can Vital Farms products be found?
How does Vital Farms support small family farms?
